TrialThe Lancet. Oncology2015
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Amit M Oza et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
427 papers cite itlatest 60 shown
this paperpooled ittrialcites it